RJA
DXCM icon

Ross\Johnson & Associates’s DexCom DXCM Stock Holding History

Ross\Johnson & Associates’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$188 Hold
3
– – ﹤0.01% 172
2025
Q4 		$199 Hold
3
– – ﹤0.01% 246
2025
Q3 		$202 Hold
3
– – ﹤0.01% 171
2025
Q2 		$262 Hold
3
– – 0.01% 157
2025
Q1 		$204 Buy
+3
New +$245 ﹤0.01% 314

Other funds holding DXCM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ross\Johnson & Associates's DXCM Position: Q1 2026 in Review

Ross\Johnson & Associates held its DexCom (DXCM) position steady in Q1 2026 at 3 shares worth $188. The position accounts for ﹤0.01% of the portfolio, ranked #172.

Ross\Johnson & Associates first reported a position in DXCM in Q1 2025 and has held it in 5 quarters since. The position peaked at $262 in Q2 2025. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Ross\Johnson & Associates held 3 shares of DexCom worth $188 as of Q1 2026.
  • Ross\Johnson & Associates left its DexCom share count unchanged in Q1 2026.
  • DexCom made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q1 2026, its #172 holding.
  • Ross\Johnson & Associates first reported a position in DexCom in Q1 2025 and has held it in 5 quarters since.
  • Ross\Johnson & Associates's DexCom position peaked at $262 in Q2 2025.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Ross\Johnson & Associates's 13F filing for Q1 2026, filed 8 May 2026.